中国难治性垂体腺瘤诊治专家共识(2019)

2019-05-21 中国垂体瘤协作组 中华医学杂志.2019.99(15):1454-1459.

2018年1月欧洲内分泌学会颁布了《难治性垂体腺瘤/垂体腺癌诊治指南》,旨在为难治性垂体腺瘤和垂体腺癌的诊断、治疗和随访,提供规范的临床指导。但其存在诊断标准不甚清晰等不足之处,该病治疗仍是一个世界性的难题,故本协作组制定《中国难治性垂体腺瘤诊治专家共识》(以下简称为本共识),以规范难治性垂体腺瘤的诊疗。

中文标题:

中国难治性垂体腺瘤诊治专家共识(2019)

发布机构:

中国垂体瘤协作组

发布日期:

2019-05-21

简要介绍:

2018年1月欧洲内分泌学会颁布了《难治性垂体腺瘤/垂体腺癌诊治指南》,旨在为难治性垂体腺瘤和垂体腺癌的诊断、治疗和随访,提供规范的临床指导。但其存在诊断标准不甚清晰等不足之处,该病治疗仍是一个世界性的难题,故本协作组制定《中国难治性垂体腺瘤诊治专家共识》(以下简称为本共识),以规范难治性垂体腺瘤的诊疗。 

拓展指南:

相关资料下载:
[AttachmentFileName(sort=100, fileName=中国难治性垂体腺瘤诊治专家共识(2019))] GetToolGuiderByIdResponse(projectId=1, id=925581c001e62105, title=中国难治性垂体腺瘤诊治专家共识(2019), enTitle=, guiderFrom=中华医学杂志.2019.99(15):1454-1459., authorId=null, author=, summary=2018年1月欧洲内分泌学会颁布了《难治性垂体腺瘤/垂体腺癌诊治指南》,旨在为难治性垂体腺瘤和垂体腺癌的诊断、治疗和随访,提供规范的临床指导。但其存在诊断标准不甚清晰等不足之处,该病治疗仍是一个世界性的难题,故本协作组制定《中国难治性垂体腺瘤诊治专家共识》(以下简称为本共识),以规范难治性垂体腺瘤的诊疗。 , cover=, journalId=null, articlesId=null, associationId=1485, associationName=中国垂体瘤协作组, associationIntro=, copyright=0, guiderPublishedTime=Tue May 21 00:00:00 CST 2019, originalUrl=, linkOutUrl=, content=<div>2018年1月欧洲内分泌学会颁布了《难治性垂体腺瘤/垂体腺癌诊治指南》,旨在为难治性垂体腺瘤和垂体腺癌的诊断、治疗和随访,提供规范的临床指导。但其存在诊断标准不甚清晰等不足之处,该病治疗仍是一个世界性的难题,故本协作组制定《中国难治性垂体腺瘤诊治专家共识》(以下简称为本共识),以规范难治性垂体腺瘤的诊疗。 </div> <div><br> </div>拓展指南:, tagList=[TagDto(tagId=92183, tagName=难治性垂体腺瘤)], categoryList=[CategoryDto(categoryId=25, categoryName=神经外科, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=null, articleKeyword=null, articleKeywordNum=null, guiderKeywordId=null, guiderKeyword=null, guiderKeywordNum=null, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=1, guiderRegion=3, opened=0, paymentType=null, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=9844, appHits=382, showAppHits=34, pcHits=3625, showPcHits=7151, likes=61, shares=14, comments=4, approvalStatus=1, publishedTime=Tue Jul 16 01:58:11 CST 2019, publishedTimeString=2019-05-21, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=1, createdBy=null, createdName=qiushida2, createdTime=Tue Jul 16 01:58:11 CST 2019, updatedBy=null, updatedName=null, updatedTime=Fri Jan 05 22:47:59 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=100, fileName=中国难治性垂体腺瘤诊治专家共识(2019))])
中国难治性垂体腺瘤诊治专家共识(2019)
下载请点击:
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1077583, encodeId=84bc10e7583e4, content=期待, beContent=null, objectType=guider, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2f052624760, createdName=gaoruiping87, createdTime=Tue Dec 07 02:02:42 CST 2021, time=2021-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=976178, encodeId=66cf9e617823, content=不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=56735429173, createdName=ms4000001683352416, createdTime=Wed Jun 23 13:00:30 CST 2021, time=2021-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=925456, encodeId=cd4592545651, content=不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200801/19f50cb64c18415eaa3f0911d2873c50/7ab97989a34747339c05d63b82d6663d.jpg, createdBy=efbb4899905, createdName=474576351, createdTime=Fri Feb 19 13:47:47 CST 2021, time=2021-02-19, status=1, ipAttribution=)]
    2021-12-07 gaoruiping87

    期待

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1077583, encodeId=84bc10e7583e4, content=期待, beContent=null, objectType=guider, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2f052624760, createdName=gaoruiping87, createdTime=Tue Dec 07 02:02:42 CST 2021, time=2021-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=976178, encodeId=66cf9e617823, content=不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=56735429173, createdName=ms4000001683352416, createdTime=Wed Jun 23 13:00:30 CST 2021, time=2021-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=925456, encodeId=cd4592545651, content=不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200801/19f50cb64c18415eaa3f0911d2873c50/7ab97989a34747339c05d63b82d6663d.jpg, createdBy=efbb4899905, createdName=474576351, createdTime=Fri Feb 19 13:47:47 CST 2021, time=2021-02-19, status=1, ipAttribution=)]
    2021-06-23 ms4000001683352416

    不错

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1077583, encodeId=84bc10e7583e4, content=期待, beContent=null, objectType=guider, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2f052624760, createdName=gaoruiping87, createdTime=Tue Dec 07 02:02:42 CST 2021, time=2021-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=976178, encodeId=66cf9e617823, content=不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=56735429173, createdName=ms4000001683352416, createdTime=Wed Jun 23 13:00:30 CST 2021, time=2021-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=925456, encodeId=cd4592545651, content=不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200801/19f50cb64c18415eaa3f0911d2873c50/7ab97989a34747339c05d63b82d6663d.jpg, createdBy=efbb4899905, createdName=474576351, createdTime=Fri Feb 19 13:47:47 CST 2021, time=2021-02-19, status=1, ipAttribution=)]
    2021-02-19 474576351

    不错

    0